Clinical trials: Second-Line
Acral Melanoma, Mucosal Melanoma
Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma
This is a prospective, single-arm, multicenter, phase II clinical trial designed to evaluate the efficacy and safety of iparomlimab and tuvoraleimab, in combination with bevacizumab, albumin-bound paclitaxel, and carboplatin as…
- Trial name
- NCT07347444
- Testing
- Iparomlimab and Tuvoraleimab injection+Bev+nab-PC
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Fudan University
Venous Thromboembolism, Cancer
Secondary Prevention of VTE in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis
This trial seeks to evaluate a management strategy after the acute treatment duration (≥ 3 months of therapeutic anticoagulation) for patients with cancer and catheter-related upper extremity deep vein thrombosis (DVT).
- Conditions
- Venous Thromboembolism, Cancer, Upper Extremity Deep Vein Thrombosis, Catheter-Related Infections
- Trial name
- STREAM-Line (NCT06603870)
- Testing
- Anticoagulation Therapy
- Where
- 2 sites in Canada
- Volunteers
- 330 people
- Sponsor
- Ottawa Hospital Research Institute
Colorectal Cancer
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
This study will evaluate whether NKTR-102, an investigational drug has an anti-tumor effect in patients with colorectal cancer. This study will also evaluate how the safety and anti-tumor activity of NKTR-102 compares with…
- Trial name
- NCT00856375
- Testing
- NKTR-102, irinotecan
- Where
- 24 sites in United States, Belgium and 4 more
- Volunteers
- 83 people
- Sponsor
- Nektar Therapeutics
Autoimmune Hemolytic Anemia, Systemic Lupus Erythematosus
Reappraisal of the Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus
There is a deficiency in guidelines about the treatment of autoimmune hemolytic anemia in systemic lupus erythematosus (SLE), especially in refractory cases.
- Trial name
- NCT05057481
- Testing
- Mycophenolate Mofetil 500mg, Rituximab
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Assiut University
Non-Squamous Non-Small Cell Lung Cancer
A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer
This single arm study will assess the safety and efficacy of Tarceva monotherapy in patients with advanced non-small cell lung cancer. Patients will receive Tarceva 150mg p.o. daily.
- Trial name
- NCT01066884
- Testing
- erlotinib [Tarceva]
- Where
- 2 sites in Russia
- Volunteers
- 5 people
- Sponsor
- Hoffmann-La Roche
HIV Infections
Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment
For treatment of human immunodeficiency virus type 1(HIV-1), publicly funded programmes tend to follow World Health Organization (WHO) guidelines to use a non-nucleoside reverse transcriptase inhibitor (NNRTI) combined with two…
- Trial name
- NCT02227238
- Testing
- DTG, LPV/RTV, Two NRTIs
- Where
- 59 sites in Argentina, Brazil and 11 more
- Volunteers
- 627 people
- Sponsor
- ViiV Healthcare
Colorectal Cancer (CRC)
Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer
This study is divided into two phases. The first phase aims to preliminarily evaluate the efficacy and safety of fruquintinib in combination with irinotecan liposome and capecitabine as second-line therapy for advanced metastatic…
- Trial name
- ARK (NCT07051785)
- Testing
- Fruquintinib+Irinotecan Liposome+Capecitabine, Bevacizumab+Irinotecan Liposome+Capecitabine
- Volunteers
- 68 people
- Sponsor
- Liu Huang
Screening for Colon Cancer, Blood Samples
Evaluation of PreveCol's Efficiency As a Second Line Method for the Early Colorectal Cancer Detection
The objective of this low-risk interventional study is to evaluate whether the PreveCol® test has sufficient efficiency to be considered as a second-line method for the detection of both colorectal cancer and advanced adenomas…
- Conditions
- Screening for Colon Cancer, Blood Samples, Survey and Questionnaire, Colorectal Carcinoma
- Trial name
- MS-Prevecol (NCT06703632)
- Testing
- blood sampling, Survey using a questionnaire.
- Where
- 2 sites in Portugal, Spain
- Volunteers
- 4,538 people, healthy volunteers welcome
- Sponsor
- ADVANCED MARKER DISCOVERY S.L.
Non-Small Cell Lung Cancer
Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer
To determine if Iscar Quercus improves immune function and quality of life among patients with stage IV non-small cell lung cancer.
- Trial name
- NCT00283478
- Testing
- Iscar Quercus, Gemcitabine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Kentuckiana Cancer Institute
BTC
Chidamide Combined With Benmelstobart, Nab-paclitaxel, and SBRT as Second-Line Treatment for Advanced BTC
This study is a prospective, single-arm, multicenter, exploratory clinical trial. It aims to evaluate the efficacy and safety of chidamide combined with benmelstobart, nab-paclitaxel, and immunogenic radiotherapy (SBRT) as…
- Trial name
- NCT07890506
- Testing
- chidamide+benmelstobart+nab-paclitaxel+SBRT
- Where
- China
- Volunteers
- 41 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Advanced Non-squamous Non-small-cell Lung Cancer, Recurrent Non-Squamous Non-Small Cell Lung Cancer
Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients
The goal of this clinical trial is to evaluate the efficacy and safety of albumin-bound paclitaxel-lenvatinib-pembrolizumab in advanced nonsquamous NSCLC patients after progression to first-line anti-PD-1/L1 inhibitor with…
- Conditions
- Advanced Non-squamous Non-small-cell Lung Cancer, Recurrent Non-Squamous Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer
- Trial name
- NCT06028633
- Testing
- pembrolizumab, lenvatinib, albumin-bound paclitaxel
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Peking University First Hospital
Postpartum Hemorrhage, Uterine Atony
Second-Line Uterotonics in Postpartum Hemorrhage: A Randomized Clinical Trial
The aim of this study is to evaluate in a randomized fashion the comparative efficacy of two second-line medications, methylergonovine and carboprost for treating atonic postpartum hemorrhage (PPH).
- Trial name
- NCT03584854
- Testing
- 15-methyl prostaglandin F2α, Methylergonovine Maleate
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Type 2 Diabetes, Cardiac Disease
Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk
We will use the target trial framework for causal inference to conduct this observational retrospective cohort study that uses claims data of adults with type 2 diabetes (T2D) included in the de-identified datasets of OptumLabs…
- Trial name
- NCT05214573
- Testing
- Glucagon like peptide 1 receptor agonist, Sodium-glucose cotransporter 2 inhibitor, Dipeptidyl Peptidase 4 Inhibitor
- Where
- United States
- Volunteers
- 386,301 people
- Sponsor
- Mayo Clinic
Mesothelioma
Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma
In patients with pleural or peritoneal mesothelioma, what is the response rate to combined Oxaliplatin (ELOXATIN®) and Gemcitabine chemotherapy?
- Trial name
- NCT00859469
- Testing
- Oxaliplatin, Gemcitabine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Columbia University
Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
This randomized phase I trial is studying the side effects and the best dose of selumetinib when given together with paclitaxel as a second line therapy in treating patients with stage IIIB-IV non-small cell lung cancer (NSCLC).
- Trial name
- NCT02503358
- Testing
- Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- OHSU Knight Cancer Institute
Biliary Cancer
Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer
The primary purpose of this study is to determine the effectiveness of SPI-1620 in combination with docetaxel in patients with advanced biliary cancer.
- Trial name
- NCT01773785
- Testing
- SPI-1620, Docetaxel
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Metastatic Colorectal Cancer
A Study of Second- and Later-line Palliative Chemotherapy in Patients With Metastatic Colorectal Cancer.
This study aims to comprehensively identify the various treatment patterns of second- or subsequent-line palliative chemotherapy used in patients with metastatic colorectal cancer who have experienced failure of first-line…
- Trial name
- NCT07263178
- Testing
- Second and later-line palliative chemotherapy
- Where
- South Korea
- Volunteers
- 1,000 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma
A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma
This is a randomized, controlled, open-label, multicenter study to evaluate efficacy of AK105 injection combined with Anlotinib Hydrochloride Capsules versus standard second-line chemotherapy.
- Trial name
- NCT04385550
- Testing
- Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection
- Where
- 45 sites in China
- Volunteers
- 528 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Colorectal Cancer
Second-Line Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Who Have Received First-Line Chemotherapy and Bevacizumab
RATIONALE: Drugs used in chemotherapy, such as irinotecan, oxaliplatin, leucovorin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- BEBYP (NCT00720512)
- Testing
- bevacizumab, fluorouracil, irinotecan hydrochloride
- Where
- 21 sites in Italy
- Volunteers
- 184 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Prostate Cancer
Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade
A growing body of literature supports the role of angiogenesis in the development and spread of a variety of human cancers including prostate cancer.
- Trial name
- NCT00945477
- Testing
- Pazopanib (GW786034)
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- Illinois CancerCare, P.C.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.